Evidence map›Paper›PMID 40811030›Full record

ArticleRheumatology (Oxford, England)2025

A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score.

Cosimo Bruni, Lorenzo Tofani, Håvard Fretheim, Sophie I E Liem, Arthiha Velauthapillai, Hilde Bjørkekjær, Imon Barua, Ilaria Galetti, Alexandru Garaiman, Mike O Becker and 6 more

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Cosimo BruniDepartment of Experimental Medicine, University of Florence, Florence, Italy.ORCID 0000-0003-2813-2083
Lorenzo TofaniDepartment of Statistics, Informatics and Applications, University of Florence, Florence, Italy.ORCID 0000-0001-9965-7667
Håvard FretheimDepartment of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.ORCID 0000-0002-0350-172X
Sophie I E LiemDepartment of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
Arthiha VelauthapillaiDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0009-0006-0700-7573
Hilde BjørkekjærDepartment of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway.ORCID 0009-0002-0321-375X
Imon BaruaDepartment of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Ilaria GalettiGILS, Gruppo Italiano per la Lotta alla Sclerodermia, Milan, Italy.ORCID 0000-0001-9595-7582
Alexandru GaraimanDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-2567-4039
Mike O BeckerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-9102-3088
Anna-Maria Hoffmann-VoldDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6467-7422
Jeska de Vries-BouwstraDepartment of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-5624-1415
Madelon C VonkDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-2266-9907
Jörg H W DistlerClinic for Rheumatology & Hiller Research Center, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany.
Marco Matucci-CerinicUnit of Immunology, Rheumatology, Allergy and Rare Diseases (UniRAR), IRCSS San Raffaele Hospital, Milan, Italy.ORCID 0000-0002-9324-3161
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310

Funding

AstraZenecaBoehringer IngelheimGruppo Italiano Lotta alla SclerodermiaNovartis Foundation for medical-biological researchScleroderma Research Foundation EP2331143Scleroderma Research Foundation US8247389
6 · The paper itself

Abstract

objectivesAs a screening tool for the presence of systemic sclerosis-associated interstitial lung disease (SSc-ILD) on high-resolution computed tomography (HRCT) is missing, we aimed to develop the ILD-RISC score, a risk algorithm to guide physicians in ordering HRCTs, with specific focus on follow-up visits.

methodsThe nominal group technique was used to select items for the multivariable logistic regression with backward selection. The ILD-RISC score was developed from baseline visits of the derivation cohort. After identifying a cut-off favoring sensitivity >85% from the ROC curve, it was validated in a separate cross-sectional cohort, and then applied longitudinally in a specific SSc cohort with negative baseline HRCT.

resultsIn the derivation cohort (533 patients), 13 variables associated with the presence of SSc-ILD on HRCT were tested. The ILD-RISC score, including FVC%, DLCO/SB%, digital ulcers ever, age and SSc autoantibodies, showed an area under the curve of 79.1% (75.3-83.0%) for the presence of SSc-ILD on HRCT. An ILD-RISC score ≥0.3 had sensitivity 85.6% and specificity 53.6%, as confirmed in the validation cohort (247 patients). Among 819 patients with negative baseline HRCT, 170 developed SSc-ILD: a low ILD-RISC score was detected in almost 50% of the follow-up visits, supporting the sparing of HRCTs.

conclusionThe ILD-RISC score was developed and validated to predict the presence of SSc-ILD. Thus, the ILD-RISC score may help to decide when to order HRCTs at follow-up, allowing the reduction of costs and radiation exposure, but also at the time of SSc diagnosis when resources are limited.

Indexed as

Lung Diseases, InterstitialScleroderma, SystemicAdultAgedAlgorithmsCross-Sectional StudiesFemaleHumansMaleMass ScreeningMiddle AgedROC CurveSensitivity and SpecificityTomography, X-Ray Computedhigh-resolution computed tomographyinterstitial lung diseasere-screeningscreeningsystemic sclerosis

Identifiers

PMID40811030
PMCPMC12671881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.